Elevar Therapeutics & Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement for Camrelizumab + Rivoceranib for uHCC
“This agreement will boost our companies’ shared focus on advancing the standard of care in uHCC, as having both camrelizumab and rivoceranib under one portfolio will significantly streamline commercialization,” said Saeho Chong, Elevar chief executive officer. “In our investigational Phase 3 CARES-310 study, the combination was shown to provide the highest reported median overall survival of any currently available uHCC treatment. Elevar’s alliance with Hengrui Pharma is a catalyst for our world-class team as we focus on bringing life-changing products to cancer patients.”
Share:
More News
Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit
“We are excited to work with Merck to advance this promising investigational combination in RAS-driven cancers,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “RAS mutations activate the RAS/MAPK pathway and promote an immunosuppressive environment. Non-clinical data suggest that targeting the pathway with ERAS-0015 may complement PD-1 blockade
“Dosing the first patient in the ASPENOVA Phase 3 clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “With DENALI Part 2 progressing toward a year-end readout that may support accelerated approval and
“The depth, durability, and consistency of responses observed across both the total population and BTKi-treated subsets underscore iopofosine’s potential as a meaningful new treatment option in WM and differentiate it from currently available therapies,” said Jarrod Longcor, chief operating officer of Cellectar Biosciences. “With the completion of at least 12-month